Lanifibranor

Modify Date: 2024-01-01 18:10:21

Lanifibranor Structure
Lanifibranor structure
Common Name Lanifibranor
CAS Number 927961-18-0 Molecular Weight 434.916
Density 1.6±0.1 g/cm3 Boiling Point 690.9±65.0 °C at 760 mmHg
Molecular Formula C19H15ClN2O4S2 Melting Point N/A
MSDS N/A Flash Point 371.6±34.3 °C

 Use of Lanifibranor


Lanifibranor is a pan peroxisome proliferator-activated receptor (PPAR) agonist with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively.

 Names

Name Lanifibranor
Synonym More Synonyms

 Lanifibranor Biological Activity

Description Lanifibranor is a pan peroxisome proliferator-activated receptor (PPAR) agonist with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively.
Related Catalog
Target

PPARγ:206 nM (EC50, Human PPARγ)

PPARδ:866 nM (EC50, Human PPARδ)

PPARα:1537 nM (EC50, Human PPARα)

In Vivo Lanifibranor is a pan peroxisome proliferator-activated receptor (PPAR) agonist with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσand PPARγ[1]. Skin fibrosis is attenuated by Lanifibranor (IVA337) (p<0.05, vehicle vs Lanifibranor at 30 mg/kg and p<0.001, vehicle vs Lanifibranor at 100 mg/kg). Both low and high doses of Lanifibranor cause a significant decrease of collagenous matrix deposition. Administration of high (100 mg/kg) doses of Lanifibranor results in reduced body weight compare with vehicle controls (p<0.05; Lanifibranor at 100 mg/kg vs vehicle). Results demonstrate that activation of Peroxisome proliferator-activated receptors (PPARs) with Lanifibranor induces a significant reduction in the infiltration of macrophages, CD45+ leucocytes and lymphocytes in Lanifibranor-treated mice compare with rosiglitazone-treated counterparts[2].
Animal Admin Male, aged 6 weeks, C57BL/6 mice are used in different animal trials. (i) Experimental dermal fibrosis (preventative model) is induced with bleomycin (n=6 each group). Concurrent treatment with local injections of bleomycin (0.5 mg/mL) and either Lanifibranor (IVA337) (30 mg/kg), Lanifibranor (100 mg/kg) or vehicle by daily oral gavage continued for 3 weeks. (ii) Experimental dermal fibrosis (curative model) is induced using subcutaneous bleomycin for 6 weeks, but 3 weeks after the first injection, mice are given a daily dose of either Lanifibranor (30 mg/kg), Lanifibranor (100 mg/kg) or vehicle by oral gavage for the remaining 3 weeks[2].
References

[1]. Boubia B, et al. Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. J Med Chem. 2018 Feb 27.

[2]. Ruzehaji N, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016 Dec;75(12):2175-2183.

 Chemical & Physical Properties

Density 1.6±0.1 g/cm3
Boiling Point 690.9±65.0 °C at 760 mmHg
Molecular Formula C19H15ClN2O4S2
Molecular Weight 434.916
Flash Point 371.6±34.3 °C
Exact Mass 434.016174
LogP 4.30
Vapour Pressure 0.0±2.3 mmHg at 25°C
Index of Refraction 1.727
Storage condition -20℃

 Safety Information

Hazard Codes N

 Synonyms

4-[1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl]butanoic acid
28Q8AG0PYL
1H-Indole-2-butanoic acid, 1-(6-benzothiazolylsulfonyl)-5-chloro-
lanifibranor
IVA-337
Top Suppliers:I want be here



Get all suppliers and price by the below link:

Lanifibranor suppliers


Price: $88/10mM*1mLinDMSO

Reference only. check more Lanifibranor price

Hot Compounds More...
Dichloromethane
CAS#:75-09-2
Polyacrylic acid
CAS#:9003-01-4
sodium carbonate
CAS#:497-19-8
Silicon dioxide
CAS#:7631-86-9
Triethanolamine
CAS#:102-71-6
Demeton
CAS#:126-75-0
Water
CAS#:7732-18-5
4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9
Diclofenac sodium
CAS#:15307-79-6
Budesonide
CAS#:51372-29-3